BUSINESS - ENTREPRENEURSHIP - INVESTING

Best Biotech Stocks To Buy Now in December 2020 – Top 7 Biotech Stocks

In this episode I review the top 7 biotech stocks in the market today.

My #1 Recommendation To Make A Full-Time Income Trading The Markets
CLICK HERE ➡️➡️➡️ https://bizwebjournal.com/ttm

★☆★ SUBSCRIBE TO ME ON YOUTUBE: ★☆★
SUBSCRIBE ➡️ https://bizwebjournal.com/Subscribe

▼ ▽ More Awesome Videos ▼ ▽

✅ For More Stock Trading Tips ➡️ https://bit.ly/3qsyfSm

Thanks for watching!

Earnings Disclaimer:
This video is for educational purposes only.The results are not typical.There is no guarantee that you will earn any money using the techniques and ideas mentioned in this video. I am not a financial advisor and anything that I say on this YouTube channel should not be seen as financial advice. Your level of success in attaining the results claimed in this video will require hard-work, experience, and knowledge. I am only sharing my biased opinion based off of speculation and my personal experience. You should always understand that with investing there is always risk. You should always do your own research before making any investment. We have taken reasonable steps to ensure that the information on this video is accurate, but we cannot represent that the website(s) mentioned in this video are free from errors. 

Transcript

Hi guys and welcome to another video. Now, if you are looking for the best biotech stocks to buy now you will want to look at the 7 biotech stocks I have got for you today.

Biotech companies utilize cutting-edge science to create medicines and treatments for a plethora of diseases, making them unique investment opportunities for investors looking to cash in on a cure. But don't think that every biotechnology investment will be an automatic slam dunk while a drug approval or a nod from the U S Food and Drug Administration can send shares of biotech stocks straight to the moon, a botched trial or poor rollout of a new medication can have dire consequences for these companies.

Smart investors will look for biotech stocks that have drug pipelines full of good prospects as well as balance sheets strong enough to withstand any unforeseen problems. So here are my seven biotech stocks to buy that fit the bill.

But before we get started, if you are new to my channel please subscribe and hit that bell notification so you will know when I release more stock trading tips and make sure you stay to the end so you don’t miss out on any of these promising biotech stocks.

The first one up is Gilead Sciences, now most of the top biotech stocks on this list have perhaps one or two drugs in the pipeline and no matter how impressive each medicine's potential may be, that isn't much diversification.

Gilead is different – the multibillion-dollar biotech behemoth provides investors with exposure to treatments for a wide range of ailments, from rheumatoid arthritis to cancer. While Gilead has long been known for its immensely profitable cure for hepatitis C, this year its antiviral remdesivir has taken center stage as the world looks to find a way to end the pandemic. Yet the future for Gilead is in its HIV treatment Biktarvy which continues to see growing demand despite the pandemic.

The diverse range of treatments in Gilead's portfolio couldn't prevent the company from posting a 10% decline in sales during the second quarter but the future remains bright for one of the biggest names in biotech.

The second biotech stock UI want to mention is Regeneron Pharmaceuticals. Regeneron has a one-two punch that investors love: short-term profitability from its drugs already on the market and long-term potential from the drugs in its pipeline. In the near term, Regeneron enjoyed a 24% increase in revenue during the second quarter.

Though sales of Eylea which is used to treat a variety of eye diseases declined a modest 6%, the product remains extremely profitable. Meanwhile, the big winner last quarter was asthma and eczema drug Dupixent, sales of which rose an impressive 70%.

Longer term, Regeneron sees a lot of potential in its oncology drug Libtayo which is a treatment for cutaneous squamous cell carcinoma but might also help those suffering from lung cancer. While investors may be focused on the hype over its REGN – COV2 cocktail Regeneron's robust pipeline means that this biotech stock still has plenty of room to run.

Moving on to the third biotech on this list which is ImmunoGen. For a biotech company like ImmunoGen positive results from drug candidates in its pipeline matter far more than what the company earns in a given quarter.

Case in point: IMGN reported a net loss of $24.3 million in the second quarter. And while that was a nearly $20 million improvement year over year, investors were less concerned with the bottom line and more focused on results from ImmunoGen's ovarian cancer treatment. Mirvetuximab soravtansine which is ImmunoGen's ovarian cancer medicine, has yielded positive results throughout the company's Soraya study which, if successful could mean accelerated approval for the drug.

Meanwhile, mirvetuximab has also been tested alongside another cancer treatment called Avastin, and phase 2 trials are proceeding nicely. The potential of ImmunoGen's cancer treatment drugs are incredible, and while the next phase of trials likely won't begin until next year investors are understandably optimistic about ImmunoGen's future.

Biotech stock number four is Crispr Therapeutics. One of the most innovative treatment techniques in the world is gene editing, and the most advanced form of gene editing today uses CRISPR technology.

CRISPR stands for clustered regularly interspaced short palindromic repeats. It allows for extremely precise genetic engineering that many scientists believe will be the key to curing a plethora of genetic disorders. Crispr Therapeutics was founded in 2013 by Emmanuelle Charpentier, one of the co-discoverers of CRISPR technology and co-recipient of the 2020 Nobel Prize in Chemistry. And while its pedigree is impressive, investors should focus on Crispr stock's bright future.

The company has a slew of promising ongoing clinical trials addressing diseases like cancer, sickle cell disease and transfusion-dependent beta-thalassemia. Any one of these could be the key to unlocking incredible profits for shareholders.

The fifth biotech stock that looks promising is Vertex Pharmaceuticals. Vertex Pharmaceuticals began 2020 with a bang when the company announced that sales of its new cystic fibrosis drug Trikafta had far outstripped what anyone was expecting, as Trikafta joined Vertex's three older cystic fibrosis drugs to give Vertex dominance over the cystic fibrosis treatment market.

Vertex's tried-and-true cystic fibrosis treatments provide the company with steady income as well as the freedom to invest in other experimental treatments – for instance, Vertex has partnered with Crispr Therapeutics to create a gene-editing therapy targeting sickle cell disease and eventually, cystic fibrosis.

Unfortunately, earlier in October Vertex halted phase 2 trials of its promising new protein-deficiency drug VX-814 due to side effects in its test subjects. Shares have plummeted 20% in the time since, but this provides new health care investors with an excellent opportunity to buy into a company with strong long-term prospects.

Moving onto the next biotech stock which is Global Blood Therapeutics. Global Blood Therapeutics has one goal: to cure sickle cell disease. That focus means that investors are putting all of their eggs in one basket labeled "Oxbryta," Global Blood's sickle cell disease medicine.

During Oxbryta's first full quarter after launch the drug brought in $14.1 million in revenue, and last quarter, that jumped quarter over quarter to $31.5 million thanks to approximately 1000 new prescriptions for the treatment.

Launching a new drug in the midst of a pandemic keeping people from visiting doctor's offices is a difficult process but Global Blood saw an "increased use of virtual engagements and telemedicine by healthcare professionals" that corresponded with increased prescriptions, and the company expects that the number of patients using Oxbryta will only continue to grow. For GBT, the growth in telemedicine is unabashedly bullish.

The last biotech stock I have for you today is Cardiff Oncology. Cardiff stock climbed 1573% this year. The oncology company is developing onvansertib for solid tumor and blood cancer indications.

The idea is to develop a treatment to overcome patient resistance to today's standard-of-care drugs. Onvansertib is a Polo-like Kinase 1 inhibitor. That means it's meant to block PLK 1 expression and therefore tumor growth. Some research has shown there may be a relationship between chemotherapy resistance and overexpression of PLK1 so Cardiff is evaluating onvansertib in combination with chemotherapy.

Most of Cardiff's share gains actually came in September after a positive clinical data report. In a phase 1 trial in a type of metastatic colorectal cancer, the onvansertib treatment controlled disease in 10 out of 11 patients. So, only one patient's disease progressed. This is encouraging but the investigational drug's human trials still are phase 2 or earlier.

Also, while PLK1 inhibitors are promising, challenges remain. This type of drug has presented issues such as toxicity at certain levels and discrepancies among study results. All of this, and the fact that onvansertib is Cardiff's only drug candidate make me cautious about the stock. I'll keep Cardiff on my watchlist but I won't consider buying until onvansertib produces positive later-stage clinical data.

So these are the best biotech stocks for this month, thanks for watching and make sure to watch the next stock trading videos that should show up right about now.

Leave a Comment: